CLOZIN (Phenomics & Genomics of CLOzapine Pharmacotherapy – INternational study)
CLOZIN is an international study on clozapine genomics and phenomics. Clozapine is generally prescribed if at least two trials of antipsychotic agents have not led to satisfactory clinical improvement. Currently, clozapine is underprescribed worldwide, mainly due to side effect concerns. This study focus on different groups of clozapine users. We make a distinction between new users, current users and former users. The overarching goal of the projects is to create predictors for clozapine outcome (response and side effects). This model includes genetic, epigenetic, and clinical data. If we know who will likely respond well without severe side-effects, doctors might use clozapine more often and earlier in the disease of patients.
For more information, visit the CLOZIN website